|Day's Range||0.520 - 0.545|
|52 Week Range||0.470 - 1.140|
|PE Ratio (TTM)||-2.10|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In a recent 10-K filing with the Securities and Exchange Commission, Douglas County-based Ampio (AMPE) said "a 'going concern' opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. Ampio is developing Ampion, an anti-inflammatory drug designed to treat to severe pain associated with osteoarthritis of the knee , which company officials are excited about. In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion, both from a regulatory perspective as well as commercial," said Michael Macaluso, chairman, and CEO, in a statement .
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has recently reported topline from its PIVOT trial and the stock lost over 60% on the announcement last Thursday. From this decline alone, it’s clear that the company didn’t report anything great, but despite missing the primary endpoint in the trial, management is shooting for an approval on the data. What […]